Hanmi Pharm Establishes 'Innovation Growth Division'... Reorganizes into Four Integrated Divisions

"Successful Launch of Obesity Treatment"

On May 8, Hanmi Pharm announced that it has implemented a comprehensive organizational restructuring to respond to the rapidly changing global pharmaceutical and biotech market environment and to efficiently achieve its core business objectives.

Exterior view of Hanmi Group headquarters. Hanmi Pharm

This restructuring aims to concretize the group-wide growth strategy presented through the Hanmi Group’s '2030 Mid-to-Long-Term Vision' announced last year. At that time, Hanmi Group had identified obesity, anti-aging, digital healthcare, and robotics as new business pillars, while planning to maximize its core business in new drug and biotech sectors. The group also revealed plans to discover new growth drivers outside of pharmaceuticals and expand inter-business linkages across the group.

As of May 1, Hanmi Pharm reorganized itself into an integrated system comprising four core divisions: Innovation Growth, Sustainable Growth, Future Growth, and Growth Support.

The centerpiece of this organizational change is the creation of the 'Innovation Growth Division.' To ensure the successful domestic and global launch of its key obesity treatment, Hanmi Pharm has integrated the New Product Development Center, Marketing Center, Pyeongtaek Manufacturing Center, Pharmaceutical Innovation Center, and Overseas Sales Team under this division to maximize synergy.

The existing R&D Center has been reorganized into the 'Future Growth Division.' This division now oversees three centers—the Obesity Metabolism Center, Oncology Center, and Convergence Center—to ensure research and development independence and to continuously identify innovative early-stage pipelines.

The Domestic Sales Division has been elevated to the 'Sustainable Growth Division,' thereby strengthening Hanmi Pharm’s external standing. This move is intended to maintain market dominance in the cardiovascular and urology fields and to secure competitiveness in new therapeutic areas. More in-depth and specialized sales activities are expected at each sales unit.

The 'Growth Support Division' encompasses the Paltan Manufacturing Center and Business Management Center to efficiently support the operations of each growth division. In particular, Hanmi Pharm has ensured the independence of clinical QA and PV teams, establishing a system that meets global standards.

Hanmi Pharm is also operating a 'Portfolio Committee' that strategically determines large-scale clinical investments. By reorganizing the Clinical Center under this committee, it will serve as a control tower that makes final decisions on the company’s overall portfolio, including new projects and product adjustments.

On May 6, Hanmi Pharm CEO Hwang Sangyeon held a town hall meeting at the company headquarters to share the purpose and details of the restructuring with employees. CEO Hwang also sent a letter to all employees, urging active cooperation and communication.

CEO Hwang stated, "This organizational restructuring is focused on breaking down departmental barriers and concentrating company-wide capabilities solely on achieving our business objectives. By establishing an integrated system where each division is organically connected, we will become a global pharmaceutical and biotech company that simultaneously realizes innovative new drug development and sustainable growth."

This content was produced with the assistance of AI translation services.